QS Investors, LLC - ACHILLION PHARMACEUTICALS IN ownership

ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 124 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.

Quarter-by-quarter ownership
QS Investors, LLC ownership history of ACHILLION PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2019$2,627,000
+66.1%
432,748
-1.5%
0.03%
+52.9%
Q3 2019$1,582,000
+34.5%
439,296
+0.1%
0.02%
+30.8%
Q2 2019$1,176,000
-11.6%
438,696
-2.4%
0.01%
-13.3%
Q1 2019$1,330,000
+86.0%
449,3030.0%0.02%
+66.7%
Q4 2018$715,000
-56.7%
449,3030.0%0.01%
-43.8%
Q3 2018$1,653,000
+30.0%
449,3030.0%0.02%
+23.1%
Q2 2018$1,272,000
-23.7%
449,303
+0.0%
0.01%
-23.5%
Q1 2018$1,667,000
+20.7%
449,250
-6.3%
0.02%
+30.8%
Q4 2017$1,381,000
-38.3%
479,363
-3.8%
0.01%
-27.8%
Q3 2017$2,238,000
+28.8%
498,335
+31.6%
0.02%
+20.0%
Q2 2017$1,738,000
+48.8%
378,570
+36.4%
0.02%
+50.0%
Q1 2017$1,168,000
+1.9%
277,5520.0%0.01%
+11.1%
Q4 2016$1,146,000
-49.0%
277,5520.0%0.01%
-50.0%
Q3 2016$2,248,000
+3.8%
277,5520.0%0.02%0.0%
Q2 2016$2,165,000
+1.0%
277,5520.0%0.02%
-10.0%
Q1 2016$2,143,000
+214200.0%
277,552
+925073.3%
0.02%
Q4 2015$1,000
-98.3%
30
-99.6%
0.00%
-100.0%
Q2 2015$60,000
-96.3%
6,778
-95.9%
0.00%
-94.4%
Q1 2015$1,627,000
-19.5%
164,8950.0%0.02%
-21.7%
Q4 2014$2,020,000164,8950.02%
Other shareholders
ACHILLION PHARMACEUTICALS IN shareholders Q3 2019
NameSharesValueWeighting ↓
MAK CAPITAL ONE LLC 5,191,600$8,255,0004.47%
RTW INVESTMENTS, LP 13,749,383$21,862,0002.04%
ARMISTICE CAPITAL, LLC 4,300,000$6,837,0000.52%
DAFNA Capital Management LLC 630,182$1,002,0000.50%
Rock Springs Capital Management LP 2,325,000$3,697,0000.18%
683 Capital Management, LLC 1,000,000$1,590,0000.10%
Alambic Investment Management, L.P. 133,698$213,0000.09%
South Dakota Investment Council 3,037,004$7,310,0000.08%
Alpine Global Management, LLC 205,172$326,0000.08%
Rhenman & Partners Asset Management AB 402,800$640,0000.07%
View complete list of ACHILLION PHARMACEUTICALS IN shareholders